Latest market price
19.48
+0.45+2.36%
Filing
Up 2.4% — Filed an 8-K material-event report (2026-11-02) — details in the filing.
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 55.66 | EPS (ttm) | 0.35 | Insider Own | 0.91% | Shs Outstand | 689.53M | Perf Week | 0.62% |
| Market Cap | 13.43B | Forward P/E | 88.28 | EPS next Y | 0.22 | Insider Trans | -0.18% | Shs Float | 686.69M | Perf Month | -0.05% |
| Enterprise Value | 22.12B | PEG | — | EPS next Q | — | Short Float | 3.16% | Perf Quarter | -9.90% | ||
| Income | 254.00M | P/S | 4.55 | EPS this Y | — | Short Ratio | 3.97 | Perf Half Y | 19.58% | ||
| Sales | 2.95B | P/B | 1.42 | EPS next Y | -52.19% | ROA | 1.17% | Short Interest | 21.73M | Perf YTD | 21.14% |
| Book/sh | 13.74 | P/C | 8.26 | EPS next 5Y | — | ROE | 3.30% | 52W High | 22.95 -15.12% | Perf Year | 10.87% |
| Cash/sh | 2.36 | P/FCF | 45.38 | EPS past 3/5Y | -52.28% -33.52% | ROIC | 16.06% | 52W Low | 15.70 24.08% | Perf 3Y | 16.37% |
| Dividend Est. | 1.22 (6.26%) | EV/EBITDA | 12.67 | Sales past 3/5Y | 11.06% 11.41% | Gross Margin | 2.53% | Volatility | 2.31% 2.40% | Perf 5Y | -43.44% |
| Dividend TTM | 1.22 (6.26%) | EV/Sales | 7.50 | EPS Y/Y TTM | 50.67% | Oper. Margin | 17.61% | ATR (14) | 0.47 | Perf 10Y | -45.66% |
| Dividend Ex-Date | Nov 13, 2026 | Quick Ratio | 2.52 | Sales Y/Y TTM | 5.55% | Profit Margin | 8.60% | RSI (14) | 52.95 | Recom | 2.54 |
| Dividend Gr. 3/5Y | -16.82% -12.66% | Current Ratio | 2.52 | EPS Q/Q | 111.76% | SMA20 | 3.01% | Beta | 0.96 | Target Price | 22.00 |
| Payout | 333.43% | Debt/Eq | 1.09 | Sales Q/Q | 11.24% | SMA50 | -1.94% | Rel Volume | 1.77 | Prev Close | 19.03 |
| Employees | 411 | LT Debt/Eq | 1.01 | Earnings | Feb 01 | SMA200 | 1.77% | Avg Volume | 5.42M | Price | 19.48 |
| IPO Date | May 23, 1985 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -68.53% — | Net Debt/EBITDA | 4.98 | Volume | 9,563,184 | Change | 2.36% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | Barclays | Equal Weight | $24 → $21 |
| Oct-13-26 | Reiterated | UBS | Neutral | $19 → $20 |
| Sep-15-26 | Reiterated | Jefferies | Hold | $17 → $21 |
| Aug-31-26 | Reiterated | Barclays | Equal Weight | $23 → $24 |
| Aug-06-26 | Reiterated | Cantor Fitzgerald | Neutral | $17 → $23 |
| Jul-15-26 | Reiterated | Wells Fargo | Equal Weight | $18 → $22 |
| Jul-07-26 | Downgrade | Barclays | Overweight → Equal Weight | $20 → $23 |
| Jul-06-26 | Reiterated | Mizuho | Outperform | $24 |
| Jun-15-26 | Reiterated | BMO Capital | Outperform | $24 |
| Jun-11-26 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $20 → $22 |
Latest News· Times ET
Nov-02-26
Nov-02-2607:01PM
06:25PM
04:05PM
Oct-29-26
Oct-22-26
Oct-20-26
Oct-19-26
04:24AM
Oct-14-26
Oct-13-26
Oct-13-2603:13AM
Oct-12-26
08:00AM
Oct-11-26
Oct-10-26
Oct-10-2611:17PM
Oct-08-26
Company
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,950 | 2,823 | 2,700 | 2,181 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,875 | 2,188 | 1,075 | 902 | — | — | — | — | — | |
| Gross Profit | 75 | 635 | 1,626 | 1,279 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 92 | 90 | 97 | 95 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | -536 | 0 | 1,057 | 750 | — | — | — | — | — | |
| Operating Income | 520 | 544 | 471 | 434 | — | — | — | — | — | |
| Interest Expense | 337 | 305 | 280 | 200 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 96 | -129 | 81 | 92 | — | — | — | — | — | |
| Net Income Before Taxes | 279 | 110 | 272 | 325 | — | — | — | — | — | |
| Income Taxes | 4 | 9 | 4 | -10 | — | — | — | — | — | |
| Consolidated Net Income | 254 | 71 | 243 | 306 | — | — | — | — | — | |
| Net Income From Continuing Operations | 275 | 101 | 267 | 335 | — | — | — | — | — | |
| Net Income | 254 | 71 | 243 | 306 | — | — | — | — | — | |
| EPS (Recurring) | 0.35 | 0.10 | 0.36 | 0.56 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.35 | 0.10 | 0.36 | 0.56 | — | — | — | — | — | |
| EPS (Diluted) | 0.35 | 0.10 | 0.36 | 0.56 | — | — | — | — | — | |
| EBITDA | 1,746 | 1,438 | 1,611 | 1,265 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 55.66 | 160.80 | 56.31 | 35.36 | — | — | — | — | — | |
| Price To Sales Ratio | 4.56 | 3.96 | 5.08 | 4.97 | — | — | — | — | — | |
| Gross Margin | 2.54 | 22.49 | 60.22 | 58.64 | — | — | — | — | — | |
| Operating Margin | 17.63 | 19.27 | 17.44 | 19.90 | — | — | — | — | — | |
| Net Margin | 8.61 | 2.52 | 9.00 | 14.03 | — | — | — | — | — | |
| Shares Outstanding | 690 | 696 | 676 | 547 | — | — | — | — | — | |
| Market Capitalization | 13,441 | 11,192 | 13,703 | 10,831 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bohn Scott R | CDO and Head of Lab | May 12 '26 | Sale | 19.45 | 10,989 | 213,740 | 7,636 | May 13 |
| Thomas John T | Director | Aug 06 '25 | Buy | 17.05 | 1,450 | 24,730 | 810,016 | Aug 06 |
| Brinker Scott M | President and CEO | Aug 04 '25 | Buy | 16.83 | 1,490 | 25,077 | 211,906 | Aug 04 |
| Brinker Scott M | President and CEO | Jul 31 '25 | Buy | 17.06 | 2,930 | 49,986 | 210,416 | Jul 31 |
| Brinker Scott M | President and CEO | Jul 28 '25 | Buy | 17.40 | 2,873 | 49,990 | 207,486 | Jul 29 |
| Thompson Tommy G | Director | May 28 '25 | Buy | 17.27 | 5,777 | 99,769 | 144,290 | May 28 |
| Thompson Tommy G | Director | May 09 '25 | Buy | 17.36 | 5,700 | 98,974 | 138,513 | May 12 |
| Brinker Scott M | President and CEO | May 09 '25 | Buy | 17.39 | 2,750 | 47,823 | 204,613 | May 12 |
| Lias-Booker Ava | Director | Apr 29 '25 | Buy | 17.83 | 5,000 | 89,150 | 35,561 | Apr 29 |
| Thomas John T | Director | Apr 28 '25 | Buy | 17.84 | 4,200 | 74,928 | 813,566 | Apr 28 |
| Sandstrom Katherine M | Director | Apr 28 '25 | Buy | 17.65 | 11,288 | 199,233 | 56,268 | Apr 28 |
| Lewis Sara Grootwassink | Director | Apr 28 '25 | Buy | 17.66 | 6,000 | 105,938 | 9,000 | Apr 28 |
| SHELLEY-KESSLER PAMELA | Director | Apr 28 '25 | Buy | 17.61 | 2,838 | 49,991 | 3,965 | Apr 28 |
| Brinker Scott M | President and CEO | Apr 28 '25 | Buy | 17.68 | 11,337 | 200,438 | 201,863 | Apr 28 |
| Lewis Sara Grootwassink | Director | Mar 04 '24 | Buy | 16.71 | 18,000 | 300,780 | 22,000 | Mar 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.